FIT Biotech Oy: Conversion of FIT Biotech Oy’s Convertible Capital Notes into shares

FIT Biotech Oy

Company release October 16, 2017 at 10:00 AM EET

Conversion of FIT Biotech Oy’s Convertible Capital Notes into shares

Related to Convertible Note and Warrant Programmes established on September 26, 2016 between the FIT Biotech Oy (“Company”) and Bracknor Investment (“Bracknor”) the Company’s board of directors have  resolved on October 13, 2017 to approve Bracknor’s request relating to the funding programme to convert EUR 40,000 worth of Convertible Capital Notes into the Company’s K shares.

Due to the conversion of the Convertible Capital Notes, the Company issues 1,371,977 new K shares in the Company to Bracknor with the conversion price of EUR 0.029155 per share.

As a result of the issue of the new K shares in the Company, the total number of shares in the Company will increase to 81,005,575 shares, and the share capital of the Company will be increased by EUR 39,999.99. After the issue of the new K shares in the Company, the Company’s shares will be divided in share series as follows: 80,935,111 K shares, 5,229 A shares and 65,235 D shares.

The increase of the share capital and new K shares in the Company will be registered in the Trade Register on or about October 17, 2017 and the new K shares will be admitted to trading on First North Finland on or about October 18, 2017.


Board of Directors

For further information:
Chairman of the Board of Directors Rabbe Slätis

Certified Advisor: Aalto Capital Partners Oy, tel. +358 40 587 7000

About FIT Biotech
FIT Biotech Oy is a biotechnology company established in 1995. The company develops and licenses its patented GTU® (Gene Transport Unit) vector technology for new-generation medical treatments. GTU® is a gene transport technology that meets an important medical challenge in the usability of gene therapy and DNA vaccines.

FIT Biotech applies GTU® technology in its drug development programmes. Application areas include cancer (gene therapy) and infectious diseases such as HIV and tuberculosis, as well as animal vaccines.

FIT Biotech shares are listed on the First North Finland marketplace maintained by Nasdaq Helsinki Oy.

Principal media

  • Steve Hamburg

    Steve Hamburg is Managing Partner / Chief Creative Officer at Calcium. In his multi-decade career, Steve has worked on a wide spectrum of pharma and consumer brands, bringing to all of them a passion for focused strategy and bold creativity.